Minirin (Desmopressin Acetate)

Desmopressin acetate is a synthetic analogue of vasopressin that selectively activates V2 receptors in the kidney’s collecting ducts. This activation raises cyclic AMP, causing aquaporin‑2 channels to move to the cell surface and increase water reabsorption. In the vascular endothelium, V2 stimulation promotes release of factor VIII and von Willebrand factor, supporting haemostasis.

The appropriate dose of Minirin is determined individually by a qualified prescriber based on the patient’s condition, age, renal function and response to therapy. Dosage regimens can vary widely, so the prescribing clinician sets the exact amount and frequency.

Safety data for Minirin in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by the treating physician.

To request Minirin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. After verification, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Minirin (desmopressin) is a selective V2‑receptor agonist, offering a more targeted effect on water reabsorption than non‑selective antidiuretic agents such as carbamazepine or chlorpropamide. It has a predictable pharmacokinetic profile and is generally preferred for central diabetes insipidus and specific bleeding disorders because it also raises clotting factors, a benefit not shared by other antidiuretics.

Minirin tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light, and store out of reach of children. Do not refrigerate or freeze the tablets.

Minirin is taken orally as a tablet. The tablet is swallowed whole with water, usually at the prescribed time of day. Patients should follow the prescriber’s instructions regarding timing relative to meals and fluid intake to optimise therapeutic effect and minimise adverse reactions.

The most serious risks include severe hyponatremia, which can lead to seizures, coma or death, and water intoxication resulting in cerebral edema. Rarely, patients may experience allergic reactions ranging from rash to anaphylaxis. Prompt monitoring of serum sodium and fluid balance is essential to detect these complications early.

Minirin is contraindicated in patients with known hypersensitivity to desmopressin acetate, those with uncontrolled hyponatremia, severe renal impairment, or conditions predisposing to fluid overload such as uncontrolled heart failure. It should also be avoided in individuals taking other potent antidiuretic agents without careful medical supervision.